Literature DB >> 10386377

Development of a new PCR-ribotyping method for Clostridium difficile based on ribosomal RNA gene sequencing.

P Bidet1, F Barbut, V Lalande, B Burghoffer, J C Petit.   

Abstract

PCR-ribotying, a typing method based on polymorphism in the 16S-23S intergenic spacer region, has been recently used to investigate outbreaks due to Clostridium difficile. However, this method generates bands of high and close molecular masses which are difficult to separate on agarose gel electrophoresis. To improve reading of banding patterns of PCR-ribotyping applied to C. difficile, a partial sequencing of the rRNA genes (16S and 23S) and intergenic spacer region has been performed, then a new set of primers located closer to the intergenic spacer region has been defined. The new PCR gave reproducible patterns of bands easy to separate on agarose gel electrophoresis. Each of the 10 serogroups and 11 subgroups of serogroup A produced a different pattern. This typing method has evidenced major qualities such as easiness, rapidity and reproducibility. However, its discriminatory power has to be evaluated to validate its importance as a typing tool for C. difficile.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10386377     DOI: 10.1111/j.1574-6968.1999.tb13629.x

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  138 in total

1.  Phenotypic and genotypic diversity of the flagellin gene (fliC) among Clostridium difficile isolates from different serogroups.

Authors:  A Tasteyre; T Karjalainen; V Avesani; M Delmée; A Collignon; P Bourlioux; M C Barc
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

2.  Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea.

Authors:  F Barbut; A Richard; K Hamadi; V Chomette; B Burghoffer; J C Petit
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

3.  Use of modified PCR ribotyping for direct detection of Clostridium difficile ribotypes in stool samples.

Authors:  Sandra Janezic; Iztok Strumbelj; Maja Rupnik
Journal:  J Clin Microbiol       Date:  2011-06-01       Impact factor: 5.948

4.  A multiplex, internally controlled real-time PCR assay for detection of toxigenic Clostridium difficile and identification of hypervirulent strain 027/ST-1.

Authors:  A M Hoegh; J B Nielsen; A Lester; A Friis-Møller; K Schønning
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-09-22       Impact factor: 3.267

5.  Clostridium difficile in piglets in the Czech Republic.

Authors:  Jana Goldová; Anna Malinová; Alexander Indra; Libor Vítek; Pavel Branny; Alena Jirásková
Journal:  Folia Microbiol (Praha)       Date:  2012-02-22       Impact factor: 2.099

6.  In vivo selection of moxifloxacin-resistant Clostridium difficile.

Authors:  Ana Mena; Elena Riera; Carla López-Causapé; Irene Weber; José L Pérez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

7.  Relapse versus reinfection: surveillance of Clostridium difficile infection.

Authors:  Mini Kamboj; Perminder Khosa; Anna Kaltsas; N Esther Babady; Crystal Son; Kent A Sepkowitz
Journal:  Clin Infect Dis       Date:  2011-10-05       Impact factor: 9.079

8.  Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes.

Authors:  Stéphanie Sirard; Louis Valiquette; Louis-Charles Fortier
Journal:  J Clin Microbiol       Date:  2011-09-28       Impact factor: 5.948

9.  Prevalence of Clostridium difficile in retail pork.

Authors:  Devon Metcalf; Richard J Reid-Smith; Brent P Avery; J Scott Weese
Journal:  Can Vet J       Date:  2010-08       Impact factor: 1.008

10.  Toxin A-negative toxin B-positive ribotype 017 Clostridium difficile is the dominant strain type in patients with diarrhoea attending tuberculosis hospitals in Cape Town, South Africa.

Authors:  B Kullin; J Wojno; V Abratt; S J Reid
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-09-30       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.